



The
**Patent
Office**

PCT/GB 99 / 03 302

15 OCTOBER 1999
INVESTING IN PEOPLE

ES ✓

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 08 NOV 1999

WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Andrew Gergey

Dated 26 October 1999

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

THIS PAGE BLANK (USPTO)

/10 98 THU 14:59 FAX 01159 552201

ERIC POTTER CLARKSON

003

Patent Form 1/77

ents Act 1977
 (s.16)

The
**Patent
 Office**

15 OCT 1998

15 OCT 1998 E397460-1 D02866
 F01/7700 0.00 - 9822458.7

Request for grant of a patent

(See the notes on the back of this form. You can also get
 an explanatory leaflet from the Patent Office to help
 you fill in this form)

The Patent Office

Cardiff Road
 Newport
 Gwent NP9 1RH

1. Your reference

15 OCT 1998
 ICOW/P19740GB
 RECEIVED BY FAX

2. Patent application number

(The Patent Office will fill in this part)

9822458.7

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Imperial College Innovations Limited
 Sherfield Building
 Imperial College
 London
 SW7 2AZ
 United Kingdom
 United Kingdom

Patents ADP number (if you know it)

If the applicant is a corporate body, give the
 country/state of its incorporation

7409436 002

4. Title of the invention

METHODS OF TREATMENT

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom
 to which all correspondence should be sent
 (including the postcode)

ERIC POTTER CLARKSON
 PARK VIEW HOUSE
 58 THE ROPEWALK
 NOTTINGHAM
 NG1 5DD

Patents ADP number (if you know it)

1305010

6. If you are declaring priority from one or more
 earlier patent applications, give the country
 and the date of filing of the or of each of these
 earlier applications and (if you know it) the or
 each application number

Country

Priority application number
 (if you know it)

Date of filing
 (day / month / year)

7. If this application is divided or otherwise
 derived from an earlier UK application,
 give the number and the filing date of
 the earlier application

Number of earlier application

Date of filing
 (day / month / year)

8. Is a statement of inventorship and of right
 to grant of a patent required in support of
 this request? (Answer yes if:

YES

a) any applicant named in part 3 is not an inventor, or
 b) there is an inventor who is not named as an
 applicant, or

c) any named applicant is a corporate body.
 See note (d))

Patent Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description

12 ✓

Claim(s)

0

Abstract

0

Drawing(s)

3 ✓

10. If you are also filing in any of the following, state how many against each item.

Priority Documents

0

Translations of priority documents

0

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

NO

Request for preliminary examination and search (Patents Form 9/77)

NO

Request for substantive examination (Patents Form 10/77)

NO

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature *Eric Potter Clarkson* Date

ERIC POTTER CLARKSON 15 October 1998

12. Name and daytime telephone number of person to contact in the United Kingdom

0115 9552211

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

METHODS OF TREATMENT

The renin-angiotensin system (RAS) is well known and is described in text books of physiology and medicine. In brief, renin acts on angiotensinogen to generate angiotensin I (ATI). This peptide is converted to angiotensin II by the action of angiotensin converting enzyme (ACE). ATII stimulates the release of aldosterone, and it is also a potent vasoconstrictor. ATII exerts at least some of its effects through the ATII receptors.

The RAS is involved in the maintenance and control of blood pressure as well as the regulation of salt and water balance.

THIS PAGE BLANK (USPTO)

ANKER 3. DOC

The renin angiotensin system (RAS) and chronic heart failure (CHF)

Early in chronic heart failure activation of the RAS occurs, initially mainly due to the introduction of heart failure treatment with drugs, particularly diuretics. It is well known that ACE inhibitors exert survival benefit in CHF patients, and one major mode of action is thought to be via its inhibiting effect on the RAS.

Recently (1997), we have shown [1] that, when considering the conventional disease severity markers peak oxygen consumption, LVEF, and NYHA class, none of these markers very strongly related to plasma renin activity and aldosterone plasma levels. However, the presence of cardiac cachexia, i.e. significant non-intentional non-oedematous weight loss (>7.5% of the previous normal weight), related closely to the presence of very high plasma renin activity and aldosterone plasma levels. Non-cachectic patients with CHF did show intermediately raised levels of plasma renin activity and aldosterone. This difference is found despite cachectic and non-cachectic patients being very similarly treated with ACE inhibitors. "ACE escape" - i.e. "angiotensin II escape" or "aldosterone escape" may be the reason, i.e. the RAS may stay activated even if patients are treated with agents blocking the main pathway of the RAS (ACE inhibitors). This finding could be particularly relevant for the development of cachectic disorders. There are no published data available on this issue in any cachectic disorder.

Aldosterone and angiotensin II may "escape" during ACE inhibitor treatment (via ACE independent pathways) [2], i.e. in the short term their plasma levels are reduced (to a varying degree), but in the long-term plasma levels may increase again.

The main bioactive element of the RAS is angiotensin II (AT II). Elevations of AT II in plasma or in local tissue would indicate conditions in which inhibition of the RAS may have significant therapeutic benefit even where partial inhibition of the RAS has been achieved (such as by therapy

with angiotensin converting enzyme [ACE] inhibitors).

RAS / AT II and wasting and weight loss in CHF patients

AT II can directly and indirectly contribute to the development of body wasting. Firstly, AT II can directly induce apoptosis, i.e. programmed cell death. Secondly, elevated AT II could on the tissue level down-regulate local production of insulin-like growth factor-I (IGF-I). IGF-I is known to be a major factor protecting against apoptosis and it is itself strongly protein anabolic.

The detrimental effects of angiotensin II and aldosterone are similar, nevertheless these adverse effects may at least in part be independent of each other. For instance, aldosterone is known to independently reduce magnesium levels by increasing urinary magnesium output, hence magnesium depletion is a prominent feature of many CHF patients [3].

Results for Angiotensin II analysis

The activation status of the RAS as a potential cause of body wasting due to underlying disease has never been studied. We have studied a variety of cachectic conditions - for instance due to chronic heart failure, AIDS, liver cirrhosis, and cancer - and we have found activation of the RAS as evidenced by elevated plasma AT II levels (mean AT II plasma levels were clearly above the upper limit of the normal range, see Figure 1). This is not dependent on any specific aetiology for the cachectic disorder, in fact we find elevated AT II plasma levels (i.e. RAS activity) also in cases of idiopathic cachexia, i.e. cachexia of unknown origin. Nevertheless, we find the activation of the RAS to be specific for cachectic disorders, as it is not seen in patients with a similar degree of weight loss consequent upon malnutrition.

Method to measure AT II:

Blood samples were collected after supine rest of at least 10 minutes. An antecubital polyethylene catheter was inserted and 10 ml of venous blood were drawn. After immediate centrifugation aliquots (EDTA plasma sample) were stored at -70°C until analysis. Angiotensin II was measured using a commercially available radioimmunoassay (IBL, Hamburg, Germany, sensitivity 1.5

pg/ml). After extraction of the plasma samples, AT II is assayed by a competitive radioimmunoassay. This radioimmunoassay is using a rabbit anti-AT II antiserum and a radioiodinated AT II tracer. Bound and free phases are separated by a second antibody bound to solid phase particles, followed by a centrifugation step. The radioactivity in the bound fractions is measured and a typical standard curve can be generated. The test has a cross-reactivity with AT I of <0.1% and a within and between run reproducibility between 3.9 and 8.6%. The reference range for healthy subjects is 20 to 40 pg/ml.

Invention / claims

to use the following drugs or procedures in humans or mammals for

the treatment or prevention of weight loss due to underlying disease (cachexia) - these underlying diseases include for example, but not restricted to AIDS, liver cirrhosis, chronic obstructive pulmonary disease with or without emphysema, chronic renal failure, chronic infections (like pneumonia), cancer (i.e. cancer cachexia), and heart disease including hypertension and chronic heart failure (i.e. cardiac cachexia), and idiopathic cachexia (i.e. cachexia due to unknown disease).

1. ACE inhibitors
2. angiotensin II receptor antagonists

to use the following drugs or procedures in humans or mammals for

- a) treatment or prevention of weight loss due to underlying disease (cachexia) - these underlying diseases include for example, but not restricted to AIDS, liver cirrhosis, chronic obstructive pulmonary disease with or without emphysema, chronic renal failure, chronic infections (like pneumonia), cancer (i.e. cancer cachexia), and heart disease including hypertension and chronic heart failure (i.e. cardiac cachexia), and idiopathic cachexia (i.e. cachexia due to unknown disease)
- b) treatment or prevention of weight loss due to the ageing process
- c) the enhancement of exercise performance in health

drugs or procedures that could reduce angiotensin II plasma levels and the activity of the RAS via mechanisms other than ACE inhibition and AT II receptor blockade

1. Any drug with an inhibiting effect on aldosterone, e.g. aldosterone antagonists (like spironolactone)
2. chymase inhibitors
3. cathepsin B inhibitors
4. renin inhibitors
5. inhibitors of ACE alternative pathways
6. exercise training
7. electrical muscle stimulation

The drugs are administered to the patient in any suitable form or by any suitable route in order to have the desired effect. The invention also includes the use of the drug in the manufacture of a medicament for treating the patient as said.

References

- ¹. Anker SD, Chua TP, Swan JW, Ponikowski P, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJS. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure: The importance for cardiac cachexia. Circulation 1997;96:526-534.
- ². Struthers AD. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 1995;16 (Suppl N):103-106.
- ³. Rahman ARA, Lang CC, Nicoll J, Struthers AD. Angiotensin II and aldosterone have opposite effects on urine magnesium output. Scot Med J 1992;37:157-158.

Drugs which inhibit the effect of aldosterone, chymase inhibitors, cathepsin B inhibitors, renin inhibitors, and inhibitors of ACE alternative pathways, are known in the art. Some are listed for example in the latest editions of the British National Formulary and in the latest edition of Martindale's Pharmacopoeia

ANKER 4. DUT

Results for noradrenaline plasma level analysis

Chronic heart failure (CHF) is a complex disorder affecting an increasing number of patients in the community with a prevalence of 10 to 30% in people over the age of 65 years [1]. Multiple physiological pathways are pathologically affected, and a series of vicious cycles have been suggested that could transform cardiac abnormalities into haemodynamic, endocrine, immunological, and muscular abnormalities that all contribute to the clinical picture of chronic heart failure [2,3,4]. One of the most studied aspects is activation of the sympathetic nervous system (SNS). Activation of the SNS can be expressed in several different ways. Apart from measuring circulating catecholamines (particularly noradrenaline, adrenaline, and dopamine), it is possible to assess sympathetic nervous excitation directly by measuring nerve impulses [5], or indirectly by analysing heart rate and blood pressure variability [6]. The technique of assessing catecholamine levels has also been developed further by assessing the catecholamine spill-over using radio-labeled tracers [7]. Nevertheless, measurement of catecholamine levels at rest are the most widely used technique. In this respect it is important to note, that noradrenaline and adrenaline are not only released from the adrenal medulla (as hormones), but that they are also neurotransmitters that are released into the synaptic cleft of sympathetic post-ganglionic nerves (therefore also termed adrenergic). Only a small proportion of the synaptically released catecholamines spills over into the circulation. Therefore measured plasma concentrations of noradrenaline and adrenaline may in some circumstances grossly underestimate the local catecholamine concentration in the adrenergic synapses.

Catecholamines: from myocardial infarction to heart failure

Sympathetic activation is well recognised to be important contributing to the development of myocardial ischaemia [8]. Cardiac β -receptors mediate increases of heart rate and inotropy, that under normal conditions lead to coronary dilation to match the oxygen demand. The direct effect of catecholamines on the coronary blood vessel is vasoconstriction mediated via α -adrenoreceptors [9]. During exercise catecholaminergic vasoconstriction is mainly mediated through circulating catecholamines and not through local hormone release [10]. After the development of coronary plaques and stenosis, the vasodilatory flow reserve is reduced and the metabolic vasodilation is

more and more and more reduced as a result of α -adrenergic coronary vasoconstriction [¹¹].

Considering the onset of an myocardial infarction as a condition of pain and mental and physical stress, it is not surprising that dramatic increases of catecholamine levels have been detected early after the onset of infarction in a variety of studies. Alone between 1969 and 1980, 15 studies with about 25000 patients and 5000 control subjects (see overview in [¹²]) have investigated plasma noradrenaline levels after myocardial infarction. Catecholamine levels peak within minutes to few hours after the onset of symptoms, and they continue to be raised for several days. The degree of the enzymatic changes during the myocardial infarction [¹³], i.e. severity of the heart attack, the early onset of ventricular arrhythmias [¹⁴], the development of cardiogenic shock [¹⁵], and of congestive heart failure [^{14,16}] are all related to plasma catecholamine levels. In patients with myocardial infarction and clinical heart failure noradrenaline remains elevated for about 1 month [¹⁷]. Sedative treatment with morphines [¹⁸], and β -blockers [¹⁹] have long been known to be able to reduce catecholamine levels during acute myocardial infarction. "Ischaemic heart disease is the most common cause of developing CHF.

When heart failure has fully developed it is then difficult to establish what exactly induces neurohormonal activation, as both the underlying disease process itself and the medication contribute to the complex hormonal alterations. Measurements in untreated patients have revealed that the sympathetic system is activated (raised catecholamine levels), but that in contrast the renin-angiotensin system is usually not activated [^{20,21}]. The initial sensor to activate these alterations remains unclear, but it is known that in the absence of a neurohormonal body response the blood pressure would fall, i.e. tissue blood perfusion would be insufficient [²²]. Therefore the initial triggers of neurohormonal activation in heart failure could be baroreceptors in the heart and aorta. When heart failure progresses other mechanisms may gain more importance. The baroreflex responses are blunted in stable chronic heart failure, whereas the peripheral and central chemoreflex sensitivity [^{23,24}] as well as the metabo-ergoreceptor reflex (afferents sensitive to skeletal muscle work load) [²⁵] deliver a strong sympathetic nervous input that may finally also lead to chronically raised catecholamine levels in severe chronic heart failure.

Catecholamines and weight loss in CHF patients

Only recently (1997), we have documented [26] that, when considering the conventional disease severity markers peak oxygen consumption, left ventricular ejection fraction (LVEF), and NYHA class, none of these markers very strongly related to resting noradrenaline and adrenaline levels. However, the presence of cardiac cachexia, i.e. significant non-intentional non-oedematous weight loss (>7.5% of the previous normal weight), related closely to the presence of raised catecholamine levels. Non-cachectic patients with CHF did on average not have elevated catecholamine levels.

Catecholamines can alter the metabolic status of the body, i.e. they can contribute to increased metabolic rates that may finally lead to a catabolic status and weight loss. This has never been considered to be a basic mechanism for body wasting in human disease in general.

Catecholamines and weight loss in wasting disorders

We have studied a variety of other cachectic conditions - for instance due to AIDS, liver cirrhosis, chronic obstructive pulmonary disease, chronic renal failure, chronic infections (like pneumonia) and cancer - and we have found activation of the SNS as evidenced by elevated plasma noradrenaline levels (mean plasma levels were clearly above the upper limit of the normal range, see Figure). This is not dependent on any specific aetiology for the cachectic disorder, in fact we find elevated noradrenaline plasma levels (i.e. SNS activity) also in cases of idiopathic cachexia, i.e. cachexia of unknown origin. Nevertheless, we find the activation of the SNS to be specific for cachectic disorders, as it is not seen in patients with a similar degree of weight loss consequent upon malnutrition.

Method to measure noradrenaline:

Blood samples were collected after supine rest of at least 10 minutes. An antecubital polyethylene catheter was inserted and 10 ml of venous blood were drawn. After immediate centrifugation aliquots (EDTA plasma sample) were stored at -70°C until analysis. Noradrenaline was measured by reverse-phase high pressure liquid chromatography (HPLC) with electrochemical detection. The detectable limit was: 0.2 nmol/l. The within batch coefficient of variance of repeated measures is less than 5%, the between batch coefficient of variance for repeated measures is 9%. The upper

limit of normal for subjects (mean + 2 standard deviations of control group: 3.31 nmol/l).

Invention / claims

to use the following drugs or procedures in humans or mammals for

- a) treatment or prevention of weight loss due to underlying disease (cachexia) - these underlying diseases include for example but not exclusively AIDS, liver cirrhosis, chronic obstructive pulmonary disease with or without emphysema, chronic renal failure, chronic infections (like pneumonia), cancer (i.e. cancer cachexia), and heart disease including hypertension and chronic heart failure (i.e. cardiac cachexia), and idiopathic cachexia (i.e. cachexia due to unknown disease)
- b) treatment or prevention of weight loss due to the ageing process

c) the enhancement of exercise performance

d) prevention of weight loss consequent to cardiovascular disorders in patients at risk of heart disease including hypertension, these drugs may be any compound that could reduce catecholamine plasma levels and the activity

of the SNS

1. Beta receptor blockers
2. imidazoline receptor antagonists (including moxonidine and rilmenidine)
3. centrally acting alpha receptor agonists like clonidine
4. peripherally acting alpha receptor antagonists
5. ganglion blocking agents
6. drugs that have effects on cardiovascular reflexes and thereby reduce SNS activity
 - opiates (via chemoreceptor)
 - digitalis alkaloids (via enhancement of baroreflex sensitivity)
 - scopolamine
 - anabolic growth factors like growth hormone and insulin-like growth factor-I (via effects on metabo-ergoreceptor)
7. ACE inhibitors
8. angiotensin receptor antagonists
9. aldosterone antagonists (like spironolactone)

dyslipidaemia,
and diabetes.
Drugs in groups
1 to 5 and 7 to 10
are useful in
this indication

10. tyrosine betahydroxylase

these procedures could be

1. exercise training

2. electrical muscle stimulation

The drugs are administered to the patient in any suitable form or by any suitable route in order to have the desired effect. The invention also includes the use of the drug in the manufacture of a medicament for treating the patient as said.

Drugs which are useful in the practice of the invention, such as those listed on pages 9 and 10 (classes 1 to 10), are well known and examples are included in the latest editions of the British National Formulary and in the latest edition of Martindale (*)

- References
1. Cowie MR, Mosterd AA, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, Grobbee DE. The epidemiology of heart failure. *Europ Heart J* 1997;18:208-225.
 2. Packer M. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. *J Am Coll Cardiol* 1992;20:248-254.
 3. Anker SD, Clark AL, Kemp M, Salisbury C, Teixeira MM, Hellewell PG, Coats AJS. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. *J Am Coll Cardiol* 1997;30:997-1001.
 4. Coats AJS, Clark AL, Piepoli M, Volterrani M, Poole-Wilson PA. Symptoms and quality of life in heart failure; the muscle hypothesis. *Br Heart J* 1994;72:S36-S39.
 5. van de Borne P, Montano N, Zimmerman B, Pagani M, Somers VK. Relationship between repeated measures of hemodynamics, muscle sympathetic nerve activity, and their spectral oscillations. *Circulation* 1997;96:4326-4332.
 6. Ponikowski P, Anker SD, Chua TP, Szelemiej R, Piepoli M, Adamopoulos S, Webb-Peploe K, Harrington D, Banasiak W, Wrabec K, Coats AJS. Depressed heart rate variability as an independent predictor of death in patients with chronic heart failure. *Am J Cardiol* 1997;79:1645-1650.
 7. Coats Adamopoulos S, Radelli A, McCance A, Meyer TE, Bernardi L, Solda PL, Davey P, Ormerod O, Forfar C, Conway J, Sleight P. Controlled trial of physical training in chronic heart failure: exercise performance, hemodynamics, ventilation, and autonomic function. *Circulation* 1992;85:2119-2131.
 8. Heusch G. α -Adrenergic mechanisms in myocardial ischaemia. *Circulation* 1990;81:1-13.
 9. Berne RM. Effect of epinephrine and norepinephrine on coronary circulation. *Circ Res* 1958;6:644-655.
 10. Chilian WM, Harrison DG, Haws CW, Snyder WD, Marcus ML. Adrenergic coronary tone during submaximal exercise in the dog is produced by circulating catecholamines. Evidence for adrenergic denervation supersensitivity in the myocardium but not in coronary vessels. *Circ Res* 1986;58:68-82.
 11. Heusch G, Deussen A. The effects of cardiac sympathetic nerve stimulation on the perfusion of stenotic coronary arteries in the dog. *Circ Res* 1983;53:8-15.
 12. Goldstein DS. Plasma noradrenaline as an indicator of sympathetic neural activity in clinical cardiology. *Am J Cardiol* 1981;48:1147-1154.


(*) Pharmacopoeia

13. Vetter NJ, Adams W, Strange RC, Oliver MF. Initial metabolic and hormonal response to acute myocardial infarction. *Lancet* 1974;1:284-289.
14. McDonald L, Baker C, Bray C, McDonald A, Restieaux N. Plasma-catecholamines after myocardial infarction. *Lancet* 1969;2:1021-1023.
15. Benedict CR, Grahame-Smith DG. Plasma adrenaline concentrations and dopamine-beta-hydrolase activity in myocardial infarction with and without cardiogenic shock. *Br Heart J* 1979;42:214-220.
16. Siggers DCM, Salter C, Fluck DC. Serial plasma adrenaline and noradrenaline levels in myocardial infarction using a new double isotope technique. *Br Heart J* 1971;33:878-883.
17. Sigurdsson A, Held P, Swedberg K. Short- and long-term neurohormonal activation following acute myocardial infarction. *Am Heart J* 1993;126:1068-1076.
18. Mueller HS, Gory DJ, Rao PS, Mudd G, Ayres SM. Cardiac catecholamine response during evolving myocardial infarct in man. *Circulation* 1980 (Suppl III);62:III-81. (abstract)
19. Mueller HS, Ayres SM. Propranolol decreases sympathetic nervous activity reflected by plasma catecholamines during evolution of myocardial infarction in man. *J Clin Invest* 1980;65:338-346.
20. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). *Circulation* 1990;82:1724-1729.
21. Remes J, Tikkanen I, Fyhrquist F, Pyorala K. Neuroendocrine activity in untreated heart failure. *Br Heart J* 1991;65:249-255.
22. Harris P. Congestive cardiac failure: central role of the arterial blood pressure. *Br Heart J* 1987;58:190-203.
23. Ponikowski P, Chua TP, Piepoli M, Ondusova D, Webb-Peploe K, Harrington D, Anker SD, Volterrani M, Colombo R, Mazzuero G, Giordano A, Coats AJ. Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure. *Circulation* 1997 Oct 21;96(8):2586-2594.
24. Chua TP, Clark AL, Amadi AA, Coats AJ. Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure. *J Am Coll Cardiol* 1996;27:650-657.
25. Piepoli M, Clark AL, Volterrani M, Adamopoulos S, Sleight P, Coats AJ. Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: effects of physical training. *Circulation* 1996 Mar 1;93(5):940-952.
26. Anker SD, Chua TP, Swan JW, Ponikowski P, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure: The importance for cardiac cachexia. *Circulation* 1997;96:526-534.

ACE inhibitors include alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, fosinopril, lisinopril, moexipril, and the like. A particularly preferred ACE inhibitor is enalapril. Angiotensin receptor antagonists include candesartan, eprosartan, losartan, valsartan and the like. A particularly preferred angiotensin receptor antagonist is losartan.

THIS PAGE BLANK (USPTO)

Figure 1



Patients with wasting disease have increased angiotensin II plasma levels

THIS PAGE BLANK (USPTO)

15/10 12:31 FAX 0171 35 733

ANOVA Table for NA model

	DF	Sum of Squares	Mean Square	F-Value	P-Value
Model	11	260.240	23.658	2.050	.0020
Error	103	825.888	8.018		

Model II estimate of between component variance: 1.798
94 cases were omitted due to missing values.

Means Table for NA model
Effect: Cachexia diag- NA-figure

	Count	Mean	Std. Dev.	Std. Err.
AIDS	8	5.217	4.801	1.660
cachectic CHF	15	4.870	3.518	.850
Cancer	2	8.888	8.058	8.573
chronic renal failure	2	3.896	4.858	3.315
COPD	14	2.843	2.305	.618
healthy controls	16	1.840	.687	.172
Idiopathic cachexia	2	3.838	3.203	2.265
Infection	8	8.437	8.888	2.844
Liverdih + Cachexia	8	8.098	5.693	2.324
Malnutrition	8	8.987	1.764	.728
more Controls	2	2.373	1.089	.834
no CHF	37	2.684	1.344	.221

Fisher's PLSD for NA model
Effect: Cachexia diag- NA-figure
Significance Level: 5 %

AIDS, cachectic CHF	
AIDS, Cancer	
AIDS, chronic renal failure	
AIDS, COPD	
AIDS, healthy controls	
AIDS, Idiopathic cachexia	
AIDS, Infection	
AIDS, Liverdih + Cachexia	
AIDS, Malnutrition	
AIDS, more Controls	
AIDS, no CHF	
cachectic CHF, Cancer	
cachectic CHF, chronic renal failure	
cachectic CHF, COPD	
cachectic CHF, healthy controls	
cachectic CHF, Idiopathic cachexia	
cachectic CHF, Infection	
cachectic CHF, Liverdih + Cachexia	
cachectic CHF, Malnutrition	
cachectic CHF, more Controls	
cachectic CHF, no CHF	
Cancer, chronic renal failure	
Cancer, COPD	
Cancer, healthy controls	
Cancer, Infection	
Cancer, Liverdih + Cachexia	
Cancer, Malnutrition	
Cancer, more Controls	
Cancer, no CHF	
chronic renal failure, COPD	
chronic renal failure, healthy controls	
chronic renal failure, Idiopathic cachexia	
chronic renal failure, Infection	
chronic renal failure, Liverdih + Cachexia	
chronic renal failure, Malnutrition	
chronic renal failure, more Controls	
chronic renal failure, no CHF	
COPD, healthy controls	
COPD, Idiopathic cachexia	
COPD, Infection	
COPD, Liverdih + Cachexia	
COPD, Malnutrition	
COPD, more Controls	
COPD, no CHF	
healthy controls, Idiopathic cachexia	
healthy controls, Infection	
healthy controls, Liverdih + Cachexia	
healthy controls, Malnutrition	
healthy controls, more Controls	
healthy controls, no CHF	
Idiopathic cachexia, Infection	
Idiopathic cachexia, Liverdih + Cachexia	
Idiopathic cachexia, Malnutrition	
Idiopathic cachexia, more Controls	
Idiopathic cachexia, no CHF	
Infection, Liverdih + Cachexia	
Infection, Malnutrition	
Infection, more Controls	
Infection, no CHF	
Liverdih + Cachexia, Malnutrition	
Liverdih + Cachexia, more Controls	
Liverdih + Cachexia, no CHF	
Malnutrition, more Controls	
Malnutrition, no CHF	
more Controls, no CHF	

Mean Diff.	Crit. Diff.	P-Value
.347	2.718	.8004
-3.148	4.588	.1783
1.582	4.588	.5119
1.374	2.748	.2573
3.277	2.688	.0174
1.582	4.588	.5514
-1.220	8.248	.4672
-.882	3.243	.6908
2.230	3.248	.1758
2.843	3.071	.1688
2.682	2.472	.0371
-3.498	4.928	.1042
1.175	4.228	.8827
1.227	2.087	.2482
2.930	2.018	.0049
1.055	4.228	.6282
-1.687	2.713	.2647
-1.228	2.713	.3713
1.893	2.713	.1716
2.487	3.652	.1663
2.286	1.719	.0099
4.870	8.816	.1022
4.723	4.248	.0268
8.426	8.812	.0031
1.923	4.368	.4082
2.267	4.588	.3292
6.378	4.588	.0250
5.892	8.127	.0224
5.781	4.077	.0053
.052	4.248	.9806
1.755	4.212	.4105
-.140	5.818	.9807
-2.742	4.588	.2384
-2.403	4.588	.3010
.708	4.588	.7600
1.822	6.127	.6103
1.111	4.077	.5900
1.703	2.068	.1083
-.192	4.248	.9285
-2.794	2.740	.0458
-2.488	2.740	.0786
.858	2.740	.8380
1.269	8.678	.4827
1.688	1.782	.2362
-1.895	4.212	.2743
-4.497	2.688	.0013
-4.188	2.688	.0026
-1.047	2.688	.4418
-.433	3.532	.6083
-.644	1.880	.4491
-2.802	4.588	.2681
-2.263	4.588	.3288
.848	4.588	.7144
1.402	5.127	.5739
1.251	4.077	.5441
.335	3.243	.8266
3.450	3.243	.0873
4.083	3.971	.0450
3.853	2.472	.0026
3.112	3.243	.0888
3.725	3.971	.0857
3.516	2.472	.0088
.813	3.971	.7600
.405	2.472	.7472
-.210	3.371	.9017

Figure 2

Individual data as
summarised in Figure 3




THIS PAGE BLANK (USPTO)

15/10 12:31 FAX 0171 351 333

Interaction Bar Plot for NA nmol/l
 Effect: Cachexia diag - NA-figure
 Error Bars: ± 1 Standard Error(e)

Figure 3.



Chronic wasting disorders show increased activity of SNS as evidenced by increased plasma noradrenaline levels

* All of these cachectic disorders have ~~been~~ mean plasma noradrenaline levels which are higher than normal

PT/GB99/03302

22/10/99 IP

Eric Potter clarkson

THIS PAGE BLANK (USPTO)